The combination of both companies capabilities creates a comprehensive biological service offering, encompassing cell line development, analytical and process development and GMP production of recombinant proteins, DNA, viruses and cell products for Phase I, II and III clinical trials. This, together with fill-finish and formulation capabilities, provides customers with a true one stop shop concept for their biologics outsourcing needs.
With the integration complete, RecipharmCobra Biologics will have cGMP approved production facilities in Keele and Oxford, UK and Sodertalje, Sweden.
Reportedly, after the transition, Simon Saxby, former CEO of Cobra Biomanufacturing, will head up RecipharmCobra Biologics in the newly formed position of vice president of Biologics.
Thomas Eldered, CEO of Recipharm, said: “Integrating the experience of Cobra Biomanufacturing’s staff, expertise and established services with our own previous offering has, we believe, created a much stronger force in the industry’s biologics outsourcing sector. Indeed, in addition to antibodies and rProteins, our integrated company competitively offers both process development and cGMP manufacturing services for viruses, DNA and cells.”